Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.
In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.
Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.
Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.
Mario Sznol, MD, from Yale University, discusses where the field of immune-oncology will be 1 and 5 years from now at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
A postsurgical circulating tumor DNA analysis after surgery and adjuvant chemotherapy may identify patients with stage III colorectal cancer at high risk of recurrence.
Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.
In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer.
Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).